← All trials
NCT06164587
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Apr 30, 2025
- First posted
- Dec 11, 2023
- Last posted
- Dec 18, 2023
- Enrollment
- 5
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of KentuckyLead sponsor
- University of KentuckyOverall official - principal investigator
- University of KentuckyReponsible party - principal investigator
- Inflammasome TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.